Acetylocholinesterase inhibitors - Beyond Alzheimer's disease;Inhibitory acetylocholinesterazy - Nie tylko w chorobie Alzheimera

Psychiatria Polska

Volumn 36, Issue 6 SUPPL., 2002, Pages 133-141

  Kłoszewska, Iwona ^a  

^a NONE

Author keywords

Acetylocholinesterase inhibitors; Alzheimer's disease; Dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CHOLINERGIC SYSTEM; COGNITION; DISEASE COURSE; DOWN SYNDROME; HUMAN; HYPERKINESIA; KORSAKOFF PSYCHOSIS; LEWY BODY; MEMORY DISORDER; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; PARKINSON DISEASE;

EID: 0036965133     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Liberini P, Memo M, Spano PF. Lewy body pathology and heterogeneity in Alzheimer's disease. J Am Med. Assoc 1995; 274: 1199.
2. Samuel W, Alford M, Hofstetter CR, Hansen LA. Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction and synapse density. J Neuropathol Exp Neurol 1997; 56: 499-508.
3. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment consortium on dementia with Lewy bodies. Neurology 1999; 53: 902-905.
4. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000; 15: 794-802.
5. McKeith I, Del Ser T, Spano PF, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
6. Liberini P, Memo M, Spano PF. Lewy body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity in Alzheimer's disease? Trends Pharmacol Sci 1996; 17: 155-160.
7. Burke W, Roccaforte W, Wengel S. Treating visual hallucinations with donepezil. Am J Psychiatry 1999; 156: 1117-1118.
8. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Namoto M, Parvez HS. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167-178.
9. Togashi H, Kimura S, Matsumoto M, Yoshioka M, Minami M, Saito H. Cholinergic changes in the hipocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996; 27: 520-526.
10. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia, 1994; 5: 163-167.
11. Tohgi H, Abe T, Kimura M, Saheki M, Kimura M. Cerbrospinal fluid acetylocholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103: 1211-1220.
12. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-169.
13. Mendez MF, Younesi FL, Perryman KM. Use of Donepezil for vascular dementia. J Neuropsychiatry Clin Neurosci 1999; 11: 268-270.
14. Tsz-Ming C, Kaufer DI. Effects of donepezil on aphasia, agnosia, and apraxia in patients with cerebrovascular lesions. J Neuropsychiatry Clin Neurosci 2001; 13: 140.
15. Bishop J, Huether CA, Torfs C, Lorey F, Deddens J. Epidemiologic study of Down syndrome in a racially diverse California population. Am J Epidemiol 1997; 145: 134-147.
16. Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KRR. Cholinergic therapy for Down syndrome. Lancet 1999; 353: 1064-1065.
17. Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium in dementia: implications for future research. J Geriatr Psychiatry Neurol 1998; 11: 159-161.
18. Wengel SP, Burke WJ, Roccaforte WH. Donepezil for postoperative delirium associated with Alzheimer's disease. J Am Geriatr Soc 1999; 3: 379-380.
19. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis patients, I: frequency, patterns and prediction. Neurology 1991; 41: 685-691.
20. Greene Y, Tariot PN, Wishart H, Cox C, Holt C, Schwid S, Noviasky J. A 12 week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000; 20: 350-356.
21. Krupp LB, Elkins LE, Scheffer RS, Smiroldo J, Coyle PK, Brook S. Donepezil for the treatment of memory impairments in multiple sclerosis. Neurology 1999; 52 (Supp 2): A137.
22. Kashemi DR, Stump DA, Jeffery DR. Effects of donepezil on cognitive function in patients with multiple sclerosis. Neurology 2001; 56 (suppl 3): A99.
23. Kopelman MD, Corn TH. Cholinergic "blocade" as a model of comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 1988; 111: 1079-1110.
24. Smith I, Hillman A. Management of alcohol Korsakoff syndrome. Adv Psychiatr Treatment 1999; 5: 271-278.
25. Angunawela II, Barker A. Anticholinesterase drugs for alcoholic Korsakoff syndrome. Int Geriatr Psychiatry 2001; 16: 337-339.
26. Iga J, Araki M, Ishimoto Y, Ohmori T. A case of Korsakoff syndrome improved by high dosesof donepezil. Alcohol Alcoholism 2001; 36, 553-555.
27. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention deficit disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409-432.
28. Levin E, Conners C, Sparrow E, Hinton S, Erhardt D, Meck W, Rose J, March J. Nicotine effects on adults with attention deficit hyperactivity disorder. Psychopharmacology 1996; 123: 55-63.
29. Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB. Adjunctive donepezil in attention deficit hyperactivity disorder in youth: Case series. J Child Adolesc Psychopharmacol 2000; 10: 217-222.
30. Hoopes SP. Donepezil for Tourette's disorder and ADHD. J Clin Psychopharmacol 1999; 19: 381-382.
31. Bortz J, Fisher RS, Blum DE, Duncan B, Burke H. Epilepsia 2000; 41 (suppl 7): 149-150.
32. Slatkin NE, Rhiner MI, Kerr C, Maluso-Bolton T. Donepezil in the treatment of opiate induced sedation: Results in 16 patients. Drugs Fut 2001; 26: 69-70.
33. Ringman JM, Cummings JL. Treatment of parasomnia with donepezil. J Neuropsychiatry Clin Neurosci 1999; 11: 134.
34. Caroff SN, Campbell EC, Havey JC, Sullivan KA, Katz IR, Mann SC. Treatment of tardive dyskinesia with donepezil. J Clin Psychiatry 2001; 62: 128-129.
35. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999; 15: 1-16.
36. Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J, George MS. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional NMR correlates. Neurocase 2001; 7: 105-110.
37. Karoff SN, Campbell EC, Havey JC, Sullivan KA, Katz IR, Mann SC. Treatment of tardive dyskinesia with donepezil. J Clin Psychiatry 2001; 62: 128-129.